Take­da wins la­bel ex­pan­sion for sub­cu­ta­neous En­tyvio, cre­at­ing 'flex­i­bil­i­ty' for Crohn's pa­tients

Pa­tients tak­ing Take­da’s En­tyvio for Crohn’s dis­ease will now have the op­tion of a sub­cu­ta­neous ver­sion.

Take­da an­nounced the la­bel ex­pan­sion on Fri­day, sev­er­al months …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.